Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury - PubMed (original) (raw)
. 2003 Mar 15;370(Pt 3):1097-109.
doi: 10.1042/BJ20021371.
Yasuhiko Yamamoto, Shigeru Sakurai, Ralica G Petrova, Md Joynal Abedin, Hui Li, Kiyoshi Yasui, Masayoshi Takeuchi, Zenji Makita, Shin Takasawa, Hiroshi Okamoto, Takuo Watanabe, Hiroshi Yamamoto
Affiliations
- PMID: 12495433
- PMCID: PMC1223244
- DOI: 10.1042/BJ20021371
Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury
Hideto Yonekura et al. Biochem J. 2003.
Abstract
The binding of advanced glycation end-products (AGE) to the receptor for AGE (RAGE) is known to deteriorate various cell functions and is implicated in the pathogenesis of diabetic vascular complications. In the present study, we show that the cellular constituents of small vessels, endothelial cells (EC) and pericytes express novel splice variants of RAGE mRNA coding for the isoforms that lack the N-terminal V-type immunoglobulin-like domain (N-truncated) or the C-terminal transmembrane domain (C-truncated), as well as the known full-length mRNA. The ratio of the expression of the three variants was different between EC and pericytes; the content of the C-truncated form was highest in EC, whereas the full-length form was the most abundant in pericytes. Transfection experiments with COS-7 cells demonstrated that those variant mRNAs were translated into proteins as deduced; C-truncated RAGE was efficiently secreted into the culture media, and N-truncated RAGE was located mainly on the plasma membrane. The three isoforms were also detected in primary cultured human EC and pericytes. Further, full-length and C-truncated forms of RAGE bound to an AGE-conjugated column, whereas N-truncated RAGE did not. The AGE induction of extracellular-signal-related kinase phosphorylation and vascular endothelial growth factor in EC and of the growth and cord-like structure formation of EC was abolished completely by C-truncated RAGE, indicating that this endogenous secretory receptor (endogenous secretory RAGE) is cytoprotective against AGE. The results may contribute to our understanding of the molecular basis for the diversity of cellular responses to AGE and for individual variations in the susceptibility to diabetic vascular complications.
Similar articles
- Identification of mouse orthologue of endogenous secretory receptor for advanced glycation end-products: structure, function and expression.
Harashima A, Yamamoto Y, Cheng C, Tsuneyama K, Myint KM, Takeuchi A, Yoshimura K, Li H, Watanabe T, Takasawa S, Okamoto H, Yonekura H, Yamamoto H. Harashima A, et al. Biochem J. 2006 May 15;396(1):109-15. doi: 10.1042/BJ20051573. Biochem J. 2006. PMID: 16503878 Free PMC article. - Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin.
Okamoto T, Yamagishi S, Inagaki Y, Amano S, Koga K, Abe R, Takeuchi M, Ohno S, Yoshimura A, Makita Z. Okamoto T, et al. FASEB J. 2002 Dec;16(14):1928-30. doi: 10.1096/fj.02-0030fje. Epub 2002 Oct 4. FASEB J. 2002. PMID: 12368225 - Blockade by phosphorothioate aptamers of advanced glycation end products-induced damage in cultured pericytes and endothelial cells.
Higashimoto Y, Matsui T, Nishino Y, Taira J, Inoue H, Takeuchi M, Yamagishi S. Higashimoto Y, et al. Microvasc Res. 2013 Nov;90:64-70. doi: 10.1016/j.mvr.2013.08.010. Epub 2013 Sep 5. Microvasc Res. 2013. PMID: 24012635 - Endogenous secretory receptor for advanced glycation end-products and cardiovascular disease in end-stage renal disease.
Nishizawa Y, Koyama H. Nishizawa Y, et al. J Ren Nutr. 2008 Jan;18(1):76-82. doi: 10.1053/j.jrn.2007.10.016. J Ren Nutr. 2008. PMID: 18089449 Review. - The AGE/RAGE axis in diabetes-accelerated atherosclerosis.
Jandeleit-Dahm K, Watson A, Soro-Paavonen A. Jandeleit-Dahm K, et al. Clin Exp Pharmacol Physiol. 2008 Mar;35(3):329-34. doi: 10.1111/j.1440-1681.2007.04875.x. Clin Exp Pharmacol Physiol. 2008. PMID: 18290873 Review.
Cited by
- On the significance of new biochemical markers for the diagnosis of premature labour.
Rzepka R, Dołęgowska B, Rajewska A, Kwiatkowski S. Rzepka R, et al. Mediators Inflamm. 2014;2014:251451. doi: 10.1155/2014/251451. Epub 2014 Dec 8. Mediators Inflamm. 2014. PMID: 25548433 Free PMC article. Review. - Reduced soluble receptor for advanced glycation end-products (sRAGE) scavenger capacity precedes pre-eclampsia in Type 1 diabetes.
Yu Y, Hanssen KF, Kalyanaraman V, Chirindel A, Jenkins AJ, Nankervis AJ, Torjesen PA, Scholz H, Henriksen T, Lorentzen B, Garg SK, Menard MK, Hammad SM, Scardo JA, Stanley JR, Wu M, Basu A, Aston CE, Lyons TJ. Yu Y, et al. BJOG. 2012 Nov;119(12):1512-20. doi: 10.1111/j.1471-0528.2012.03463.x. Epub 2012 Aug 20. BJOG. 2012. PMID: 22900949 Free PMC article. - AGEs/sRAGE, a novel risk factor in the pathogenesis of end-stage renal disease.
Prasad K, Dhar I, Zhou Q, Elmoselhi H, Shoker M, Shoker A. Prasad K, et al. Mol Cell Biochem. 2016 Dec;423(1-2):105-114. doi: 10.1007/s11010-016-2829-4. Epub 2016 Oct 6. Mol Cell Biochem. 2016. PMID: 27714575 Clinical Trial. - Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule.
Schlueter C, Weber H, Meyer B, Rogalla P, Röser K, Hauke S, Bullerdiek J. Schlueter C, et al. Am J Pathol. 2005 Apr;166(4):1259-63. doi: 10.1016/S0002-9440(10)62344-9. Am J Pathol. 2005. PMID: 15793304 Free PMC article. - RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases.
Koyama H, Yamamoto H, Nishizawa Y. Koyama H, et al. Mol Med. 2007 Nov-Dec;13(11-12):625-35. doi: 10.2119/2007-00087.Koyama. Mol Med. 2007. PMID: 17932553 Free PMC article. Review.
References
- Circulation. 1997 Nov 18;96(10):3737-44 - PubMed
- Arch Ophthalmol. 1961 Sep;66:366-78 - PubMed
- Nat Med. 1998 Sep;4(9):1025-31 - PubMed
- J Mol Biol. 1998 Oct 23;283(2):489-506 - PubMed
- Cell Mol Biol (Noisy-le-grand). 1998 Nov;44(7):1013-23 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases